Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy

Abstract

Background

HAART has reduced mortality in HIV-infected patients; however, the risk of non-AIDS-related events has increased, including cancer. We compared mortality in HIV-infected patients with or without cancer with the general population in Italy.

Methods

Eligible patients were recorded in the San Raffaele Infectious Diseases Department database. The ratio of observed deaths to expected all-cause deaths (standardized mortality ratio [SMR]) was standardized for age and gender, and stratified by cancer occurrence or year of HIV infection (≤1998 or >1998). Expected all-cause deaths were obtained from the Istituto Superiore di Sanità (Rome, Italy; 2002 data).

Results

Among 6,495 HIV-infected patients, contributing 75,171 person-years, the SMR was 6.0 (95% CI 5.7, 6.4); SMRs decreased as age increased. Mortality rates were significantly higher than the general population for patients with or without cancer (SMR=15.1 [95% CI 13.6, 16.7] and 4.8 [95% CI 4.5, 5.1], respectively). For patients with or without cancer, SMRs were higher in those aged <45 years than older patients. SMRs for patients with cancer were almost stable in those infected with HIV ≤1998 (15.3; 95% CI 13.7, 17.0) or >1998 (13.5; 95% CI 9.2, 19.1). Among patients with cancer diagnosed with HIV >1998, age-adjusted SMRs ranged from 216.0 (95% CI 43.4, 631.3) to 6.8 (95% CI 4.7, 9.7) in patients <30 years or ≥70 years, respectively.

Conclusions

Mortality in HIV-infected patients remains higher than the general population in Italy, with marked differences according to age, and cancer contributing to an increased excess of mortality.

References

Egger

, Hirschel

, Francioli

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194–1199.

Mocroft

, Ledergerber

, Katlama

Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–29.

Mocroft

, Vella

, Benfield

T.L.

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725–1730.

Palella

F.J.

Jr. , Baker

R.K.

, Moorman

A.C.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860.

Valdez

, Chowdhry

T.K.

, Asaad

Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin Infect Dis 2001; 32: 1487–1493.

van Sighem

, Danner

, Ghani

A.C.

Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005; 40: 212–218.

van Sighem

A.I.

, van de Wiel

M.A.

, Ghani

A.C.

Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17: 2227–2236.

Panos

, Samonis

, Alexiou

V.G.

Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res 2008; 6: 257–260.

10.

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293–299.

11.

Currier

J.S.

, Lundgren

J.D.

, Carr

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118: e29–e35.

12.

Grinspoon

Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003; 37 Suppl 2: S85–S90.

13.

Holmberg

S.D.

, Moorman

A.C.

, Williamson

J.M.

Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747–1748.

14.

Lichtenstein

K.A.

, Ward

D.J.

, Moorman

A.C.

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389–1398.

15.

Mondy

, Yarasheski

, Powderly

W.G.

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36: 482–490.

16.

Sackoff

J.E.

, Hanna

D.B.

, Pfeiffer

M.R.

, Torian

L.V.

Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397–406.

17.

Silverberg

M.J.

, Abrams

D.I.

AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19: 446–451.

18.

Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387–1396.

19.

Data Collection on Adverse Events of Anti-HIV Drugs D:A:D Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537–1548. Erratum 2011; 25: 883.

20.

Cáceres

, Cruz-Amy

, Díaz-Meléndez

AIDS-related malignancies: revisited. P R Health Sci J 2010; 29: 70–75.

21.

Grulich

A.E.

Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009; 4: 183–187.

22.

Cinti

S.K.

, Gandhi

, Riddell

4th . Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier? AIDS Read 2008; 18: 18–20., 26–32.

23.

Clifford

G.M.

, Polesel

, Rickenbach

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425–432.

24.

Franceschi

, Lise

, Clifford

G.M.

Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103: 416–422.

25.

Long

J.L.

, Engels

E.A.

, Moore

R.D.

, Gebo

K.A.

Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 489–496.

26.

Bonnet

, Burty

, Lewden

Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48: 633–639.

27.

Monforte

, Abrams

, Pradier

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143–2153.

28.

Bruyand

, Thiebaut

, Lawson-Ayayi

Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109–1116.

29.

Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1–19.

30.

Rothman

, Boice

Epidemiologic analysis with a programmable calculator. NIH Publ 79-1649. Washington, DC: US Government Printing Office 1979.

31.

Lohse

, Hansen

A.B.E.

, Pedersen

Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 87–95.

32.

Sterne

J.A.

, Hernan

M.A.

, Lederberger

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378–384.

33.

Crum

N.F.

, Riffenburgh

R.H.

, Wegner

Comparison of causes of death and mortality rates among HIV-infected persons: analysis of pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194–200.

34.

Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624–1633.

35.

Jaggy

, von Overbeck

, Ledergerber

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877–878.

36.

Jensen-Fangel

, Pedersen

Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18: 89–97.

37.

Keiser

, Taffe

, Zwahlen

All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18: 1835–1843.

38.

Lewden

, Raff

, Chene

, Sobel

, Leport

Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. J Acquir Immune Defic Syndr 2001; 26: 480–482.

39.

Marin

, Thiebaut

, Bucher

H.C.

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743–1753.

40.

Lewden

, Chene

, Morlat

HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72–77.

41.

French

A.L.

, Gawel

S.H.

, Hershow

Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51: 399–406.